Authors: M. Taha, S.R. Singh, C. Butler, E. Nyairo, V.A. Dennis
Affilation: Alabama State University, United States
Pages: 217 - 220
Keywords: Chlamydia, rMOMP, PLGA
The design of an immunization regimen capable of inducing sustained genital mucosal Th1 response is the current goal for a vaccine for humans to control the severe complications of genital infection by C. trachomatis. In this research, gene fragments of the MOMP gene containing T and B-cell epitopes (corresponding to amino acids 187 – 344) were expressed in E. coli cells, purified and encapsulated in PLGA 50:50 nanoparticles. The efficacy of rMOMP-187–PLGA nanoparticles was evaluated in vitro in J774 macrophages. Our data shows that rMOMP-187 encapsulated in PLGA 50:50 nanoparticles has the potential to induce immune responses in vivo and hence further studies are underway to confirm its usefulness as a promising vaccine candidate against Chlamydia. The anticipated results will provide the foundation for full- scale research on the antibody immunity characteristics of recombinant MOMP-PLGA as a potential candidate against Chlamydia.